NCT05380323View on ClinicalTrials.gov

A Study of LY3541105 in Healthy and Overweight Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

May 10, 2022

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions
OverweightHealthy
Interventions
DRUG

LY3541105

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (2)

66219

PRA International, Lenexa

78209

ICON Early Phase Services, San Antonio

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY